Catalyst Pharmaceuticals Inc

NASDAQ:CPRXUnited States

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.

Contact Information

Headquarters

355 ALHAMBRA CIRCLE, SUITE 801CORAL GABLES, FL, United States 33134

Phone

305-529-2522

Fax

302-636-5454

Executives

Non-Executive Chairman of the Board

Patrick Mcenany

Chief Executive Officer, Director

Richard Daly

Chief Financial Officer, Executive Vice President, Treasurer

Michael Kalb

Executive Vice President, Chief Operating Officer, and Chief Scientific Officer

Steven Miller

Executive Vice President, Chief Commercial Officer

Jeffrey Del Carmen